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Objectives: To characterize cognitive impairment in primary progressive multiple 
 sclerosis (PPMS) and to correlate the pattern of cognitive deficits with brain magnetic 
resonance imaging (MRI) volumetric data.
Materials and methods: In a multicenter cross- sectional study, we recruited consecu-
tive patients with PPMS as well as age, sex, and education level- matched healthy 
 controls (HC). All participants underwent neuropsychological (NP) assessment, and 
brain MRI was performed in patients with PPMS for analysis of lesion load, subcortical 
GM volumes, and regional cortical volumes.
Results: We recruited 55 patients with PPMS and 36 HC. Thirty- six patients were in-
cluded in the MRI analysis. Patients with PPMS performed significantly worse than HC 
in all NP tests. Subcortical GM volume was significantly correlated with all NP tests, 
except for Stroop Test, with the largest effect for the thalamus (r=−.516 [BVMT- R DR, 
P=.016 FDR- corrected] to r=.664 [SDMT, P<.001 FDR- corrected]). In the stepwise 
linear regression model, thalamic volume was the only predictor of performance in all 
NP tests.
Conclusion: Cognitive impairment is common in PPMS and affects all evaluated cogni-
tive domains. Subcortical GM volume, particularly of the thalamus, is a strong  predictor 
of cognitive performance, suggesting it has a central role in the pathophysiology of 
PPMS- related cognitive dysfunction.
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1  | INTRODUCTION
Cognitive impairment has been increasingly recognized as a frequent 
cause of disability in multiple sclerosis (MS) in all stages of the disease, 
with a profound impact on activities of daily living and quality of life.1,2 
It is reported to be present in 15- 65% of patients with MS,3,4 depending 
on different cognitive impairment definitions and disease subtypes.1,5,6
Due to the relative rarity of primary progressive multiple sclero-
sis (PPMS),7 the impact of cognitive dysfunction on this MS subtype 
has not yet been fully investigated. The few studies assessing cognitive 
impairment in PPMS estimate a frequency of cognitive dysfunction 
ranging from 7% to 50% 2,4,8 and affecting several domains, including 
attention and working memory, verbal learning, spatial memory, spa-
tial reasoning, and verbal fluency.4,5,9–12 Most of these studies rely on 
small single- center samples, which may account for the widely varying 
frequency of cognitive impairment and equivocal results when com-
paring PPMS with other MS subtypes. In addition, data regarding mag-
netic resonance imaging (MRI) correlates of cognitive dysfunction in 
PPMS are scarce. In relapse- onset MS, it is widely recognized that MRI 
measures of white matter (WM) and gray matter (GM) atrophy are cor-
related with cognitive dysfunction, generally with GM volume indices 
accounting for most of the variance.13 However, patients with PPMS 
have MRI characteristics that differ from those with relapse- onset MS, 
with relatively low burden and activity of MRI- visible lesions on T2- 
weighted and gadolinium- enhanced scans of the brain,14 and therefore, 
these results cannot be directly extrapolated. A few studies have in-
vestigated the relationship between MRI findings and cognitive impair-
ment in PPMS. Ukkonen and colleagues15 found cognitive deficits in 
patients with PPMS to be correlated with T1- and T2- lesion load, but 
not with global brain atrophy, while in a more recent study by Tur et al., 
GM damage as measured by magnetization transfer ratio was the main 
correlate of overall cognitive dysfunction.16 The influence of individual-
ized subcortical GM structures and regional cortical atrophy on PPMS- 
related cognitive impairment, however, remains to be determined.
The purpose of our study was to characterize cognitive impair-
ment in patients with PPMS and to correlate the pattern of cognitive 
deficits with brain MRI volumetric data.
2  | MATERIALS AND METHODS
2.1 | Study population and setting
In a multicenter, hospital- based, cross- sectional study, we re-
cruited patients with PPMS regularly followed at the Department of 
Neurology of six Portuguese centers, namely (a) Centro Hospitalar 
e Universitário de Coimbra (CHUC); (b) Centro Hospitalar de Vila 
Nova de Gaia/Espinho (CHVNG/E); (c) Centro Hospitalar de São João 
(CHSJ); (d) Centro Hospitalar de Lisboa Central (CHLC); (e) Centro 
Hospitalar de Setúbal (CHS); and (f) Centro Hospitalar de Entre Douro 
e Vouga (CHEDV).
Patients were consecutively recruited during a six- month period 
from April to September 2014. Inclusion criteria were as follows: defi-
nite diagnosis of PPMS according to the 2010 McDonald criteria17; 
age between 18 and 65; and native Portuguese speaker.
A group of healthy volunteers, matched through age, sex, and edu-
cation level stratification with patients with PPMS, were recruited and 
served as healthy controls (HC).
Exclusion criteria for all participants were a history of neurologic 
(other than MS in patient group) or systemic disease; a significant vi-
sual, auditory, or language impairment that would negatively affect 
their ability to satisfactorily complete tests or understand test instruc-
tions; a history of psychiatric illness, with the exception of stable mild 
to moderate depressive symptoms; starting or stopping antidepres-
sants in the 2 months prior to the assessment; a history of alcohol, 
drug, or substance abuse; a history of previous head injury resulting in 
loss of consciousness; a recent cognitive evaluation (within 1 year); a 
relapse or steroid treatment within 30 days preceding evaluation.
This study was approved by local ethics committees and by the 
Portuguese Data Protection Authority, and all participants or their le-
gally authorized representatives gave written informed consent.
2.2 | Clinical assessment
A full medical history and detailed neurologic examination were ob-
tained for all patients. The following clinical and demographic data 
were collected: age, years of education, sex, handedness, age of dis-
ease onset, age at diagnosis, disease duration, and current disease- 
modifying treatment. Physical disability was evaluated using the 
detailed Kurtzke Expanded Disability Status Scale (EDSS).18 For HC, 
medical history was obtained by interview prior to assessment.
2.3 | Neuropsychological evaluation
All participants underwent a neuropsychological (NP) evaluation, 
which was performed in a single session and using the same test order 
in all centers. The battery comprised the oral version of the Symbol 
Digit Modalities Test (SDMT)19,20 to evaluate information process-
ing speed; the Brief Visuospatial Memory Test—Revised (BVMT- R)21 
to assess visuospatial learning and memory; the California Verbal 
Learning Test (CVLT1)22 to evaluate verbal learning and memory; and 
the Stroop Test 23,24 for executive function (inhibitory control). This 
battery is similar to The Brief International Cognitive Assessment for 
Multiple Sclerosis (BICAMS),25 with the addition of the Stroop Test.
Additionally, the Beck Depression Inventory (BDI) 26,27 and the 
Modified Fatigue Impact Scale (MFIS)28 were used to determine the 
influence of depression and fatigue, respectively.
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2.4 | MRI acquisition and analysis
Brain MRI was performed in patients with PPMS, within 3 months of 
cognitive evaluation. MRI acquisition was performed in five centers 
using the same acquisition parameters and protocol. MRI scans were 
analyzed by three neuroradiologists blinded for clinical and NP results.
Patients were examined on 1.5- Tesla MRI scanners (Siemens® 
Magnetom Avanto, Siemens® Magnetom Symphony and Philips® 
Inter), using 2- 18 coil channels for the acquisition of the following 
sequences: axial T2- weighted fluid- attenuated inversion recovery 
(FLAIR) images; axial T2- weighted turbo spin- echo images; axial pro-
ton density- weighted images; and three- dimensional (3D) isotropic 
T1- weighted fast gradient echo images with magnetization- prepared 
inversion recovery pulse (MP- RAGE). Scans were obtained in an axial- 
oblique orientation, parallel to the subcallosal line.
Global and regional atrophy measures were acquired via brain ex-
traction and tissue segmentation techniques using the 3D MP- RAGE 
images and the FreeSurfer software v5.3.0 (freely available at http://
surfer.nmr.mgh.harvard.edu/). The process has been described previ-
ously29–32 and demonstrated good test–retest reliability across scanner 
manufacturers and field strengths.33 Skull- stripping and segmentation 
were checked and manually corrected whenever necessary. Volumetric 
data were normalized to the estimated total intracranial volume and 
included the following individualized structures: total GM, total neo-
cortical GM, total subcortical GM, total WM, frontal cortex, parietal 
cortex, occipital cortex, temporal cortex, cingulate cortex, subcortical 
GM nuclei (caudate, putamen, globus pallidus, thalamus, and nucleus 
accumbens), corpus callosum, lateral ventricles, and III ventricle.
The T1 lesion volumes were obtained with the FreeSurfer soft-
ware, as described above, using the “T1 white matter hypointensities” 
volume output. T2 lesion load was measured by experienced observ-
ers, who manually contoured the WM lesions slice by slice on the 
FLAIR acquisition series, using the 3D Slicer software (v4.3.1, freely 
available at http://www.slicer.org).34
2.5 | Statistical analysis
Categorical variables are reported as absolute (n) and relative frequen-
cies (%), and continuous variables are expressed as mean and stand-
ard deviation (SD) for variables with a normal distribution, or median 
and interquartile range (IQR) otherwise. Normality was assessed both 
visually and through the Kolmogorov- Smirnov test.
Categorical variables were analyzed using the chi- square (χ2) test 
or the Fisher exact test (as appropriate). An independent- samples t 
test was used to compare normally distributed continuous variables; 
for variables with a non- normal distribution, a Mann- Whitney U test 
was performed. In addition, an analysis of covariance (ANCOVA) was 
performed adjusted for BDI and MFIS scores for between- group com-
parison of NP performance.
For each NP score, z- scores were calculated according to the following 
formula: (patient’s score - mean value of HC group matched for age, sex, and 
education level)/SD of the matched HC. Impairment in a given NP test was 
defined as a z- score below the fifth percentile of the matched HC group.
Pearson’s correlation (or Spearman correlation if normality was not 
assumed) was used to assess the correlation between NP performance, 
clinical variables, and MRI data, controlled for age and education level.
To account for possible confounders and interactions between 
variables, a forward stepwise linear regression model (entrance cri-
terion P<.05 and exit criterion P=.10) was generated in order to de-
termine which MRI variables (lesion load and regional volumes) were 
predictors of cognitive performance on each NP test. In each case, 
age and education were entered as covariates and retained in block 1. 
Significant variables in the correlation analysis were entered in block 2 
using the forward stepwise technique.
Statistical analyses were performed using IBM SPSS Statistics for 
Windows, version 22.0 (IBM Corp, Armonk, NY, USA). All tests were 
two- tailed, with statistical threshold set at P<.05 for single tests or at 
P<.05 corrected through false discovery rate (FDR) for multiple testing.
3  | RESULTS
3.1 | Demographic and clinical description of 
population
Ninety- eight patients with PPMS were identified in the six centers in-
volved in this study. Forty- three were excluded for the following rea-
sons: age over 65 years16; refusal to participate12; severe dementia5; 
severe physical disability5; psychiatric disease3; history of head injury 
resulting in loss of consciousness1; and presence of other conditions 
that could impair cognition.1
Fifty- five patients with PPMS (22 from CHUC, six from CHVNG/E, 
five from CHSJ, 13 from CHLC, four from CHS, and five from CHEDV) 
and 36 matched HCs were included. Demographic characteristics 
of all participants and main clinical features of the PPMS group are 
shown in Table 1.
3.2 | Cognitive performance
Patients with PPMS performed worse than their matched HC in all 
NP tests (Table 2). Regarding depression and fatigue measures, pa-
tients with PPMS had significantly higher BDI and MFIS scores than 
HC (P<.001).
After controlling for the effect of BDI and MFIS scores using 
ANCOVA analysis, the differences between patients with PPMS and 
HC remained significant in all NP tests except for visual learning 
(BVMT- R TL): Stroop C: F(1,87)=5.7, P=.019; Stroop CW: F(1,87)=7.7, 
P=.007; CVLT TL: F(1,87)=10.2, P=.002; CVLT DR: F(1,87)=12.8, 
P=.001; BVMT- R TL: F(1,87)=2.9, P=.095; BVMT- R DR: F(1,87)=5.9, 
P=.017; SDMT: F(1,87)=11.0, P=.001.
In the group of patients with PPMS, 42 (76.36%) were impaired in 
at least one NP test (six [10.90%] patients failed in one NP test, eight 
[14.55%] patients in two NP tests, and 28 [50.90%] patients in three 
or more NP tests), while in HC, impairment in one or more NP tests 
was found in 10 (27.78%).
Correlation analysis in patients with PPMS, controlled for age 
and education, did not reveal significant correlations between clinical 
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variables (including disease duration, age of MS onset, EDSS, BDI, and 
MFIS scores) and performance on NP tests (P>.05 FDR- corrected). 
Similarly, sex distribution was not associated with significant differ-
ences in all NP tests.
3.3 | Brain MRI parameters and cognitive 
performance in patients with PPMS
Of the 55 patients with PPMS included, 42 underwent brain MRI. In 
the other 13 patients, MRI could not be performed due to technical 
limitations,5 patient refusal,5 and claustrophobia.3
The group of patients that was not able to undergo MRI was not 
significantly different from the remaining sample regarding age, sex 
distribution, education, disease duration, and EDSS (Table S1).
Brain structures and lesion load volumes are shown in Table 3. 
Correlations between brain MRI variables and cognitive tests in patients 
with PPMS, controlled for age and education, are presented in Table 4.
Subcortical GM volume was significantly correlated with the score 
of all NP tests, with the largest effect for thalamic volume ranging 
from r=−.516 (BVMT- R DR, P=.016 FDR- corrected) to r=.664 (SDMT, 
P<.001 FDR- corrected). Conversely, total neocortical GM was only 
modestly correlated with visuospatial learning (BVMT- R TL, r=.380, 
P=.04 FDR- corrected).
Regarding WM, total volume was not significantly correlated with 
any NP test. On the other hand, corpus callosum volume was sig-
nificantly correlated with the majority of cognitive domains, ranging 
from r=−.429 (BVMT- R TL, P=.048 FDR- corrected) to r=.531 (SDMT, 
P<.001 FDR- corrected).
The Stroop Test did not correlate significantly with any corti-
cal region or subcortical structure for a statistical threshold at P<.05 
FDR- corrected and therefore was not analyzed further on regression 
models.
The regression models predicting performance on NP tests were 
controlled for the effects of age and education (Table 5). In each case, 
only those MRI variables that were statistically significant in the cor-
relation analysis were entered into the models. Thalamic volume was 
the only predictor of performance in all NP tests.
4  | DISCUSSION
In the present study, we have characterized the cognitive profile of 
a multicenter cohort of patients with PPMS and compared it with a 
matched group of HC. Patients with PPMS performed significantly 
worse than their matched HC in all evaluated cognitive domains, 
which is in agreement with previous studies.5,11,15
In an attempt to investigate the pathophysiology of cognitive im-
pairment in PPMS, we analyzed the contribution of several brain MRI 
parameters in this group of patients, including conventional measures 
of lesion load and WM and GM volumetric measures. To the best of 
our knowledge, this is the first study assessing the influence of indi-
vidualized subcortical GM structures and regional cortical atrophy in 
PPMS- related cognitive impairment.
TABLE  2 Comparison of cognitive performance in patients with 
PPMS and HC
PPMS  
N=55
HC  
N=36 P value
Stroop
C (median [IQR]) 84.0 (69- 342) 65.0 (56- 110) <.001
CW (median 
[IQR])
175.0 (142- 505) 135.0 (118- 260) <.001
CVLT1 TL 
(mean ± SD)
40.2 (13.4) 52.6 (9.6) <.001
CVLT1 DR 
(mean ± SD)
9.0 (3.9) 12.7 (1.8) <.001
BVMT- R TL 
(mean ± SD)
17.6 (10.2) 23.1 (5.9) .005
BVMT- R DR 
(median [IQR])
7.0 (4- 12) 10.0 (9- 12) .002
SDMT 
(mean ± SD)
32.5 (16.7) 47.4 (12.0) <.001
BDI (median [IQR]) 11.0 (6- 26) 4.0 (0- 14) <.001
MFIS (mean ± SD) 36.5 (18.4) 9.7 (19.9) <.001
PPMS, primary progressive multiple sclerosis; HC, healthy controls; Stroop 
C, Stroop color naming; Stroop CW, Stroop color- word naming; CVLT1 TL, 
California Verbal Learning Test - first edition, total learning; CVLT1 DR, 
California Verbal Learning Test - first edition, delayed recall; BVMT- R TL, 
Brief Visuospatial Memory Test - Revised, Total Learning; BVMT- R DR, 
Brief Visuospatial Memory Test - Revised, Delayed Recall; SDMT, Symbol 
Digit Modalities Test; BDI, Beck Depression Inventory; MFIS, Modified 
Fatigue Impact Scale; SD, standard deviation; IQR, interquartile range.
Data are given as raw scores.
P values are corrected for multiple comparisons by false discovery rate 
method. P values with statistical significance are indicated in bold.
TABLE  1 Demographic characteristics of all participants and 
clinical features of the PPMS group
PPMS  
N=55
HC  
N=36 P value
Mean age, years 
(mean ± SD)
52.7 ± 9.1 51.2 ± 8.6 .433
Education level, years 
(median [IQR])
9.0 (4- 17) 9.0 (4- 18) .720
Female, n (%) 31 (56.4) 18 (50.0) .668
Caucasian, n (%) 55 (100.0) 35 (97.2) .396
Right- handed, n (%) 54 (98.2) 35 (97.2) >.900
Age of disease onset,  
years (median [IQR])
42.0 (35- 53) – 
Disease duration, 
years (median [IQR])
11.0 (7- 25) – 
EDSS (median [IQR]) 6.0 (4- 7.5) – 
Patients on disease- 
modifying treatment, 
n (%)
33 (60)
PPMS, primary progressive multiple sclerosis; HC, healthy controls; EDSS, 
Kurtzke Expanded Disability Status Scale; SD, standard deviation; IQR, in-
terquartile range.
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The results obtained suggest that GM damage is important in 
PPMS, appearing as the main contributor to the related cognitive 
impairment, beyond the influence of WM pathology. On the other 
hand, it is noteworthy that subcortical GM volumes, particularly of the 
thalamus, accounted for most of the variance in cognitive tasks per-
formance, even when compared with cortical GM volumes. Executive 
function performance, measured by the Stroop Test, did not correlate 
significantly with any cortical region or subcortical structure, probably 
reflecting that this complex cognitive domain requires a dynamic inter-
play of several large- scale neural networks, hindering the possibility of 
capturing it with a pure MRI volumetric approach. Additionally, mea-
surement accuracy is lower for small volumes and may have compro-
mised the assessment of the contribution of individual GM structures 
to executive functions. In the remaining cognitive domains (episodic 
verbal learning and memory, information processing speed, and visu-
ospatial learning and memory), thalamic volume emerged as the only 
independent predictor of dysfunction.
Since the original conceptualization by Alexander et al.,35 of parallel 
cortico- basal ganglia- thalamocortical loops connecting the basal gan-
glia and the thalamus to the frontal cortex, the role of these structures 
TABLE  4 Correlation between MRI parameters and NP performance in patients with PPMS, controlling for age and education
Volumes StroopC Stroop CW CVLT1 TL CVLT1 DR BVMTR TL BVMTR DR SDMT
T2 lesion load 0.367 0.376* −0.371 −0.327 −0.405* −0.358 −0.540**
T1 lesion load 0.054 0.05 −0.385* −0.402* −0.425** −0.471** −0.356*
Total neocortical GM 0.010 0.187 0.087 0.001 0.380* 0.369 0.158
Frontal cortex −0.073 −0.039 0.197 0.081 0.319* 0.396* 0.189
Parietal cortex 0.104 0.210 −0.059 −0.115 0.352* 0.283 0.073
Temporal cortex −0.056 0.111 0.155 0.131 0.336* 0.325* 0.133
Occipital cortex 0.100 0.199 −0.063 −0.169 0.344* 0.383* −0.026
Cingulate gyrus 0.257 0.359* 0.124 0.156 0.172 0.095 0.057
Total subcortical GM −0.357 −0.363 0.450 0.455 0.407* 0.406 0.662***
Thalamus −0.294 −0.329* 0.579*** 0.525** 0.560*** 0.516** 0.664***
Putamen −0.181 −0.174 0.369* 0.322* 0.382* 0.365* 0.354*
Caudate −0.262 −0.386* 0.065 −0.112 0.011 0.022 0.222
Globus pallidus −0.140 −0.256 0.390* 0.421** 0.286 0.336* 0.340*
N. accumbens −0.069 0.017 0.304 0.290 0.246 0.305 0.255
Total White matter −0.283 −0.194 0.142 0.148 0.125 0.205 0.205
Corpus Callosum −0.253 −0.336 0.475* 0.438* 0.429* 0.400 0.531***
Stroop C, Stroop color naming; Stroop CW, Stroop color- word naming; CVLT1 TL, California Verbal Learning Test - first edition, total learning; CVLT1 DR, 
California Verbal Learning Test - first edition, delayed recall; BVMTR TL, Brief Visuospatial Memory Test - Revised, Total Learning; BVMTR DR, Brief 
Visuospatial Memory Test - Revised, Delayed Recall; SDMT, Symbol Digit Modalities Test; GM, gray matter.
All correlations are Pearson r coefficients. Statistical significance is indicated in bold. *P<.05; **P<.01; ***P<.001 (corrected for multiple testing by false 
discovery rate method).
Total neocortical GM 0.26045 ± 0.02389 Total white matter 0.28605 ± 0.02713
Frontal cortex 0.04682 ± 0.00379 Corpus Callosum 0.00146 ± 0.00051
Parietal cortex 0.03009 ± 0.00400 Lateral ventricles 0.00985 ± 0.00506
Temporal cortex 0.03086 ± 0.00327 III ventricle 0.00116 ± 0.00048
Occipital cortex 0.01327 ± 0.00127
Cingulate gyrus 0.00630 ± 0.00064
Total subcortical GM 0.03241 ± 0.00292
Thalamus 0.00411 ± 0.00041
Putamen 0.00264 ± 0.00043
Caudate 0.00216 ± 0.00028
Globus pallidus 0.00081 ± 0.00011 T2 lesion load 14459.68 ± 11041.10
N. accumbens 0.00024 ± 0.00006 T1 lesion load 6489.93 ± 4966.82
PPMS, primary progressive multiple sclerosis; GM, gray matter.
The values shown are the ratio between absolute volumes and total intracranial volume, except for T2 
and T1 lesion load (mm3). Data are given as mean ± standard deviation.
TABLE  3 Brain strutures and lesion 
load mean volumes of patients with PPMS
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in cognition has been emphasized. In line with this, previous studies 
in relapse- onset MS examining the influence of subcortical GM struc-
tures on cognition have revealed a strong correlation between these 
and cognitive performance.13 Among subcortical GM structures, the 
thalamus has shown the strongest correlation with cognitive impair-
ment in MS studies.36 In PPMS, it has been reported that, in clinically 
early disease, atrophy is most prominent in subcortical GM structures, 
particularly in the thalamus, with cortical and infratentorial atrophy 
developing later as the disease progresses.37 More importantly, it has 
been demonstrated that thalamic damage independently predicts 
long- term accumulation of disability in PPMS.38 Our study is the first to 
suggest that thalamic volume is a significant predictor of PPMS- related 
cognitive impairment. Interestingly, thalamic volume was an indepen-
dent predictor of verbal and visuospatial memory, which are typically 
impaired in conditions affecting the mesial temporal cortex. The thal-
amus, specifically the anterior and dorsomedial nuclei, is part of the 
Papez circuit and therefore is a critical structure for episodic memory. 
Recent theories propose a reciprocal connection between the hippo-
campus and the thalamus, the latter being implicated in executive as-
pects of episodic memory (selection of to- be- coded information and 
retrieval strategies),39 which could offer some explanation for our data.
There are some limitations to our study to be considered. First of 
all, it is limited by the cross- sectional design. Second, although the 
same clinical procedures and MRI acquisition parameters were used 
in all centers, there could have been some variability that the small 
sample size could not overcome. Third, the relatively modest sam-
ple size may have prevented us from fully examining the influence 
of other variables on cognitive performance. Moreover, the use of 
stepwise linear regression procedures has some limitations, particu-
larly the propensity to overfit the data and the fact that the models 
created may be an over- simplification of the real ones. Finally, we did 
not assess other MRI variables that may have accounted for variance 
in cognitive performance, such as GM demyelinating lesions, and 
measures of diffuse occult disease by MRI spectroscopy, magnetiza-
tion transfer, and diffusion tensor imaging of normal- appearing brain 
tissue.
Apart from these concerns, our study furthers the knowledge 
of cognitive dysfunction in PPMS and its respective underlying 
mechanisms. We conclude that cognitive impairment is common in 
PPMS and affects several cognitive domains including information 
processing speed, visual memory, verbal memory, and executive func-
tions. Subcortical GM volume, particularly of the thalamus, was the 
strongest predictor of cognitive impairment, suggesting it has a crucial 
contribution to cognition in PPMS.
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